Back to results
US 12,460,207 B2Granted
Inhibiting APE2 expression in a subject treated with a drug agent that causes increased APE2 expression
AssigneeThe Cleveland Clinic Foundation
InventorsJianjun Zhao, Jianhong Lin
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, systems, articles of manufacture, and methods of treating a subject with: i) an APE2 inhibitor, and ii) a drug agent that causes increased expression of APE2 in said subject. In certain embodiments, the drug agent is Cisplatin or similar drug.
Claims5
A method of protecting kidney function in a subject comprising:
- treating a subject having cisplatin-treated cancer with:
- i) an apurinic/apyrimidinic endonuclease 2 (APE2) inhibitor, wherein said APE2 inhibitor comprises:
- i) an antisense oligonucleotide directed toward APE2 mRNA or DNA, or ii) an siRNA sequence directed toward APE2 mRNA, and
- ii) a drug agent that causes increased expression of APE2 in said subject, wherein said drug agent comprises cisplatin,
- and wherein said subject is administered an amount of said drug agent that is at least 15 mg/kg, and causes acute kidney injury in said subject in the absence of said APE2 inhibitor, and
- wherein said APE2 inhibitor is administered before said drug agent.
3 more elements
Dependencies are inferred from the claim text.